SAB
SAB US
Stock
Stock
Ticker: SABS
SABS
Price
Price
CHART BY
Frequently asked questions
What is SAB US's market capitalization?
The market capitalization of SAB US is $276.60M. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
What is the Earnings Per Share (EPS) for SAB US?
SAB US's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -$1.66. EPS indicates the company's profitability on a per-share basis.
What are the analyst ratings and target price for SAB US's stock?
Currently, 12 analysts cover SAB US's stock, with a consensus target price of $11.75. Analyst ratings provide insights into the stock's expected performance.
What is the EBITDA for SAB US?
SAB US's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -$68.71M. EBITDA measures the company's overall financial performance.
What is the free cash flow of SAB US?
SAB US has a free cash flow of -$57.44M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
How many employees does SAB US have, and what sector and industry does it belong to?
SAB US employs approximately 86 people. It operates in the Health Care sector, specifically within the Biotechnology industry.
What is the free float of SAB US's shares?
The free float of SAB US is 81.53M. Free float refers to the number of shares available for public trading, excluding restricted shares.
Financials
- Market Cap
- $276.60M
- EPS (TTM)
- -$1.66
- Free Float
- 81.53M
- EBITDA (TTM)
- -$68.71M
- Free Cashflow (TTM)
- -$57.44M
Pricing
- 52W span
- $2.45$5.15
Analyst Ratings
The price target is $11.75 and the stock is covered by 12 analysts.
Buy
12
Hold
0
Sell
0
Information
SAB Biotherapeutics, Inc. is a clinical-stage, biopharmaceutical company, which engages in advancing a new class of immunotherapies leveraging fully-human polyclonal antibodies. It produces human polyclonal immunotherapies and its versatile DiversitAb platform is applicable for unmet needs in human diseases. The company was founded by Eddie J. Sullivan and Christine E. Hamilton in July 2014 and is headquartered in Miami Beach, FL.
- Employees
- 86
- Industries
- Biotechnology
- Sector
- Health Care
Identifier
- Primary Ticker
- SABS
Fundamentals & EOD data from FactSet